About Vita Therapeutics

Vita is progressing its lead program, VTA-100 for the treatment of limb-girdle muscular dystrophy (LGMD2A). Vita is developing this proprietary cellular therapies following a dual development strategy beginning with autologous-derived cells before moving to a universal hypoimmunogenic cell line.

We are a team of dedicated scientists striving to advance treatments in multiple indications within our cell therapy platform.

Vita Therapeutics was originally founded out of the labs of Dr. Gabsang Lee and Dr. Kathryn Wagner at Johns Hopkins University and the Kennedy Krieger Institute in 2019 by Douglas Falk, MS and Peter Andersen, PhD.